Devilish Details: Icahn Looks To Boost Bristol/ImClone Offer
• By The Pink Sheet
Pity Carl Icahn. The biotech industry's best-known activist shareholder and chairman of ImClone saw the value of his holdings plummet following the Food and Drug Administration's 2001 rejection of the company's lead cancer drug, the EGFR inhibitor Erbitux (cetuximab), and the succeeding insider-trading scandal that sent CEO Sam Waksal to jail
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
